生物制药公司Arvinas Holding Company LLC（股票代码：ARVN）今日盘中股价大跌5.05%，引起市场广泛关注。
这一显著跌幅很可能与加拿大蒙特利尔银行（BMO）最新发布的研究报告有关。BMO虽然维持了Arvinas的"优于大市"评级，但大幅下调了其目标价，从此前的20美元降至10美元，降幅高达50%。
如此大幅度的目标价下调无疑打击了投资者信心。尽管BMO仍然看好Arvinas的长期发展前景，但目标价的大幅下调可能反映出分析师对公司短期内面临的挑战持谨慎态度。投资者可能需要密切关注Arvinas未来的业务发展和财务表现，以评估公司的长期投资价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.